Emedgene

Palo Alto,  CA 
United States
http://www.emedgene.com
  • Booth: 1108

Emedgene provides solutions that interpret genetic tests automatically, helping geneticists manage their growing workload faster and with higher accuracy. This is achieved with an interpretable ML engine that has learned to perform genomics research, after training with millions of data points from patient cases, databases, and the most recent genomics publications. Labs using Emedgene reduce time spent on interpretation and reporting and increase yield without increasing headcount.

Brands: Emedgene automates the variant interpretation workflow, pinpointing causative variants with evidence, curating literature and extracting phenotypes, helping labs scale interpretation and discovery.


 Press Releases

  • September, 2019 – Palo Alto, California — Greenwood Genetic Center utilizes Emedgene’s AI to slash turnaround times, improve diagnostic yield and return answers to patients faster. Emedgene’s platform automates much of the genomic analysis workflow, allowing Greenwood to reduce time-per-test by 75%.

    Greenwood Genetic Center is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects based in South Carolina. The center is actively investing in technology initiatives that faculty have deemed critical to improving patient care and remaining at the forefront of genomic medicine, with the ultimate goal of increasing diagnostic yield and ending the diagnostic odyssey for more patients. Their diagnostic lab offers an extensive menu of genetic tests, among others, diagnosing patients served by South Carolina’s Department of Disabilities and Special Needs.  

    Analyzing genetic tests, and in particular, exome tests, was a time consuming and labor-intensive effort performed by Greenwood’s highly skilled personnel. The analysis process required them to review dozens of variants. Specifically challenging was searching for recently discovered gene-disease connections in databases and the literature. Facing longer turnaround times, Greenwood’s lab directors set out to incorporate advanced technology that would help prioritize variants, provide access to an up-to-date database of gene-disease associations, and shorten analysis time. 

    Emedgene’s AI Solves All Test Cases During Evaluation

    The team evaluated a dozen genomic analysis platforms according to a stringent set of criteria, and 4 platforms were selected for a performance assessment on a set of 10 previously solved cases, some of which were intentionally complex. “Emedgene was the only vendor able to automatically solve all 10 cases,” says Julie Jones, PhD, Greenwood’s Clinical Genomic Sequencing Program Director. “Other vendors’ prioritization algorithms were successful in roughly 30% of cases.” 

    Emedgene’s interpretable machine learning algorithms provide a short-list of causative variants, along with supporting evidence. The evidence includes current information curated from the literature using Natural Language Processing, as well as information from databases, animal models and pathways, providing a comprehensive – yet completely automated – review. “Emedgene’s machine learning simplifies the highly complex task of variant analysis, allowing us to handle more tests every day,” says Ray Louie, PhD, Assistant Director in the Center’s Molecular Diagnostic Laboratory. 

    “It’s been a pleasure to collaborate with such an excellent team of scientists, supporting the advanced work they are doing in clinical interpretation, and constantly pushing the boundaries to meet a higher diagnostic yield. We consider scaling genomic interpretation a key factor in enabling advanced genomic medicine to patients in need, and have found with Greenwood a true partnership for advancing this goal,” says Einat Metzer, CEO of Emedgene. 

  • Less than 40% of genetic cases are solved initially; Emedgene's new algorithm ‘Pathorolo’ enables automated reanalysis of past cases by identifying the cases most likely to be solved

    Palo Alto, California – October 11, 2019 — Emedgene, the world’s first completely automated genetic interpretation platform, announces the launch of Pathorolo, its unique machine learning algorithm capable of determining the likelihood of a genomic case to be solved with available information. This includes the most recent scientific literature curated automatically using Natural Language Processing. 

    Pathorolo will enable labs to automate reanalysis, by focusing valuable geneticist time only on cases with high chances of positive outcomes. On the flip side, Pathorolo can clearly demark cases that are unlikely to be solved, allowing the interpretation team to recognize when to stop researching, since the available information won’t allow a genomic case to be solved. In clinical use, the model can both improve yield and reduce time-spent-per-case. 

    Pathorolo gives each case a score which is associated with the probability of being solved, and allows labs to set their own analysis thresholds. The model was trained and validated with large datasets of clinical cases.

    “Pathorolo is a new and unique layer of explainable AI, and we are really excited to share more details during ASHG event in Houston,” says Dr. Shay Tzur, Chief Science Officer of Emedgene. “Emedgene’s AI is already able to pinpoint causative variants, now it can also identify when a genomic case is likely to be solved. The algorithm is essentially scoring itself, which is extremely useful in evaluating its output.”

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.